Original ArticleChanges in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic Individuals
Section snippets
Materials and Methods
The study population has been described previously.6 In summary, individuals with a best-corrected VA letter score between 68 and 25 (approximate Snellen equivalent between 20/50 and 20/320) in the study eye and DME involving the center of the macula for whom the investigator judged macular photocoagulation could be safely withheld for 16 weeks were included. Subjects were excluded if they had untreated high-risk proliferative diabetic retinopathy, were judged likely to need scatter
Baseline Information and Treatments
Of 172 participants in the phase II DME study, 19 were noted at baseline to have retinal neovascularization by the Photograph Reading Center. One of these 19 individuals (enrolled as a protocol deviation) was excluded from this report because scatter photocoagulation was applied 13 days before randomization (0.3-mg group), and 2 additional subjects were excluded because follow-up photographs were not available (1 in the 3-mg group and 1 in the sham group).
Of the remaining 16 subjects (Table 1),
Discussion
To our knowledge, this is the first report to be published in the peer-reviewed literature documenting regression of retinal neovascularization as observed on fundus photographs and angiograms in individuals with diabetic retinopathy after selective VEGF165 blockade. Specifically, pegaptanib sodium, an anti-VEGF aptamer that selectively binds VEGF165, given as a series of intravitreous injections, was followed by regression of neovascularization or loss of neovascularization as determined on
References (12)
- et al.
Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision
Ophthalmology
(2003) - et al.
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
Am J Ophthalmol
(1994) - et al.
Spontaneous regression of neovascularization at the disk and elsewhere in diabetic retinopathy
Am J Ophthalmol
(1996) Preliminary report on effects of photocoagulation therapy
Am J Ophthalmol
(1976)Early photocoagulation for diabetic retinopathy. ETDRS report number 9
Ophthalmology
(1991)- et al.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
N Engl J Med
(1994)
Cited by (231)
Eye-on-a-chip
2023, Principles of Human Organs-on-ChipsSpermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy
2019, Pharmacological ResearchTyphae pollen polysaccharides ameliorate diabetic retinal injury in a streptozotocin-induced diabetic rat model
2018, Journal of EthnopharmacologyAnti-Vascular Endothelial Growth Factor Therapy for Diabetic Eye Disease
2018, Current Management of Diabetic RetinopathyThe Clinical Importance of Changes in Diabetic Retinopathy Severity Score
2017, OphthalmologyCitation Excerpt :Indeed, the rationale for anti-VEGF therapy for DME follows data showing that VEGF levels were increased in the retina and vitreous of eyes with DR.28 Furthermore, increased vitreous and plasma VEGF levels have been shown to be prognostic of worsening in patients with PDR undergoing vitrectomy.28 In 1 multicenter study, most subjects with retinal neovascularization at baseline who were assigned to the pegylated anti-VEGF aptamer pegaptanib for the treatment of DME also showed regression of neovascularization during follow-up.29 Thus, the current evidence suggests that anti-VEGF therapy targets one of the major underlying pathologic pathways in DR that is responsible not only for worsening DME, but also for worsening of DR severity.
Manuscript no. 2005-796.
The study was sponsored by Eyetech Pharmaceuticals, Inc., New York, New York, and Pfizer Inc., New York, New York.
- 1
Correspondence to Neil M. Bressler, MD, Suite 115, 550 North Broadway, Baltimore, MD 21205-2002. E-mail: [email protected].
Reprint requests to Michael Altaweel, MD, 2870 University Avenue, Suite 206, Madison, WI 53705. E-mail: [email protected].
- ⁎
Members of a Writing Committee from the Study Group, chaired by Michael Altaweel, MD (University of Wisconsin, Madison, Wisconsin), take authorship responsibility for this article, had complete access to the data needed for it, and are listed in the “Appendix” with pertinent financial conflicts of interest.